Eisai Mediaroom

Month Year

Dec 22, 2022

EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...
Dec 19, 2022

EISAI TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA® (perampanel) CIII IN UNITED STATES TO CATALYST PHARMACEUTICALS

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the...
Dec 14, 2022

EISAI AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ENTER INTO COMPREHENSIVE RESEARCH COLLABORATION AGREEMENT AIMING TO CREATE NEW THERAPIES FOR NEURODEGENERATIVE DISEASES

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research...
Dec 1, 2022

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN®, "eribulin") will be presented during the 2022 San Antonio...
Nov 29, 2022

EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...
Nov 29, 2022

ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...
Nov 23, 2022

EISAI TO PRESENT LATEST DATA ON FYCOMPA® (PERAMPANEL) CIII AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will have a total of 34 posters, including the latest data on its in-house discovered and...
Nov 20, 2022

EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMER'S DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker findings from the company's Phase 3 confirmatory Clarity AD clinical trial for...
Oct 21, 2022

Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

Data Include Provider-Reported Best Overall Response (BOR), Progression-Free Survival and Overall Survival in U.S. Patients NUTLEY, N.J., Oct. 21, 2022 /PRNewswire/ -- Eisai today announced final...
Sep 27, 2022

Lecanemab Confirmatory Phase 3 CLARITY AD Study Met Primary Endpoint, Showing Highly Statistically Significant Reduction Of Clinical Decline In Large Global Clinical Study Of 1,795 Participants With Early Alzheimer's Disease

ALL KEY SECONDARY ENDPOINTS ALSO MET, DEMONSTRATING HIGHLY STATISTICALLY SIGNIFICANT RESULTS PROFILE OF AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA) INCIDENCE WAS WITHIN EXPECTATIONS EISAI AIMS TO...
Sep 10, 2022

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022

RAHWAY, N.J. and NUTLEY, N.J., Sept. 10, 2022 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the...
Sep 10, 2022

Eisai Presents Results of Post-Hoc Analysis of Eribulin Mesylate (HALAVEN®) at the European Society for Medical Oncology (ESMO) Congress 2022

Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Studies (Presentation: #259P) NUTLEY, N.J., Sept. 10, 2022 /PRNewswire/ -- Eisai announced today results...
Sep 6, 2022

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022

Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular...
Aug 23, 2022

C2N and Eisai Collaborate to Build Awareness and Real-World Evidence for Blood-Based Assays for Cognitive Impairment in Clinical Practice Outside of Clinical Trial Settings

C2N Diagnostics and Eisai Inc. today announced the Companies have entered into a memorandum of understanding that will seek to build awareness about how blood-based assays for cognitive...
Aug 18, 2022

Eisai Inc. Reinforces Commitment to Collaboration and Innovation to Support Patients and Communities Through New U.S. Headquarters

State-of-the-art Eisai US hhceco Center underscores New Jersey as the premier life science hub NUTLEY, N.J., Aug. 18, 2022 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai...
- Photos 1
Aug 4, 2022

Eisai Partners with Baseball Legend to Help Support People Living with Liver Cancer

Campaign Provides Educational Resources on Liver Cancer and Encourages People to Make Some Daily Adjustments to Help Support Liver Health NUTLEY, N.J., Aug. 4, 2022 /PRNewswire/ -- Baseball legend...
- Photos 2
Aug 3, 2022

Eisai Presents New Findings On Lecanemab's Investigational Subcutaneous Formulation And Modeling Simulation Of APOE4 Genotype On ARIA-E Incidence At The Alzheimer's Association International Conference (AAIC) 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced that...
Aug 3, 2022

Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

RAHWAY, N.J. and NUTLEY, N.J., August 3, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the Phase 3 LEAP-002 trial investigating...
Jul 27, 2022

Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership

Thomas D. Fagan Jr. Appointed Vice President, U.S. Alzheimer's Disease Commercial at Eisai Inc. NUTLEY, N.J., July 27, 2022 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai...
- Photos 1
Jul 25, 2022

Eisai To Present The Latest Lecanemab Data, Including ARIA-E And Subcutaneous Formulation, And Other Alzheimer's Disease Research At The Alzheimer's Association International Conference (AAIC) 2022

Eisai Co. Ltd (Headquarters: Toyoko, CEO: Haruo Naito, "Eisai") announced today that the company will present research from its Alzheimer's disease (AD) pipeline, including new data for lecanemab...
Jul 25, 2022

AB-related Paper Published in the American Scientific Journal Science

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that lecanemab, an anti-amyloid-β protofibril antibody being developed by Eisai, has no connection regarding...
Jul 5, 2022

The U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...
Jun 21, 2022

Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal

Second Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its...
Jun 5, 2022

Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting

Poster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202)...
- Photos 1
Jun 2, 2022

Eisai to Present Latest Data on LEMBOREXANT at the 36th Annual Sleep 2022 Meeting

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today a total of seven poster presentations including the latest data on its in-house discovered orexin receptor...

RECENT RELEASES

Sep 14, 2024

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone Late-breaking first interim analysis...

Sep 4, 2024

Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024, Including First Interim Analysis Results from the Phase 3 LEAP-012 Trial

Late-breaking results from the Phase 3 LEAP-012 trial offer further insight into the treatment of patients with unresectable, non-metastatic hepatocellular carcinoma (HCC); data are selected for...

Aug 22, 2024

Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

FOR GLOBAL MEDIA AND JOURNALISTS OUTSIDE THE EMEA REGION In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD)...